ScanSource (SCSC) Q4 2026 Earnings Call Transcript

ScanSource delivered record non-GAAP EPS of $1.46 (+43% YoY) on Q4 net sales of $953.1M (+17% YoY), with full-year free cash flow of $113.8M (124% conversion) and net leverage around zero. Management guided FY2027 organic revenue growth of 6%–10% and adjusted EBITDA of $158M–$165M (4.6%–4.65% margin), plus at least $85M in FCF (excluding MicroAge). The company also agreed to acquire MicroAge for $220.5M all-cash to expand cloud, cybersecurity and AI services, while continuing disciplined capital returns with $97.9M of buybacks in FY2026 and ~$121M remaining authorization.

Analysis

SCSC is turning from a pure hardware distributor into a channel-integrated services platform, which matters because the margin pool is migrating toward implementation, managed services, and recurring connectivity rather than box-moving. The MicroAge deal is less about near-term synergies than about changing the company’s attach rate: if even a modest share of partner-originated security/cloud deals convert into services-led pull-through, gross profit per transaction can rise faster than revenue, supporting a higher multiple despite only mid-single-digit organic growth.

The immediate winner is SCSC itself, but the second-order beneficiaries are vendors that need implementation capacity and recurring attach, especially networking/security names that are constrained by partner capability more than demand. The losers are smaller VARs/TSDs that compete primarily on commission economics; once partners can bundle fulfillment plus support through a larger platform, simple pricing arbitrage becomes less defensible. HPE’s Juniper breadth helps validate the networking cycle, but the supply constraint comment suggests that benefit shifts right by at least one quarter and may be more useful for order visibility than current-period revenue.

The key risk is that investors over-rotate on the acquisition headline and underappreciate integration drag, channel conflict, and the fact that the FY27 guide excludes the acquired earnings stream. In the next 1-3 months, the stock likely trades on whether management can quantify MicroAge’s EBITDA quality and whether buybacks remain meaningful after the cash outlay; over 6-18 months, the question is whether services mix can lift consolidated EBITDA margin above the current low-mid single-digit trajectory. Falsifier: if FY27 organic growth falls below 6% or if Q1/Q2 shows gross margin dilution from mix or integration costs, the re-rating case breaks.

Contrarian view: consensus may be treating this as a straightforward growth-and-balance-sheet story, but the more important point is capital allocation discipline. With leverage near zero and buybacks still authorized, management has optionality to absorb integration risk; if the acquired asset performs as advertised, SCSC is effectively buying a higher-ROIC services layer at a valuation that is likely below what the public market would assign standalone. The market may be underpricing the structural shift from distributor multiple to platform multiple, but that rerating only sticks if services revenue becomes visible in reported numbers, not just in commentary.

Key Decisions for Investors

• Long SCSC on post-earnings weakness or any pullback toward the pre-gap VWAP; target 10-15% upside over 3-6 months if FY27 organic growth holds and MicroAge closes on schedule; stop if guidance is cut below 6% organic growth or margin guidance compresses.
• Use a 3-6 month call spread on SCSC only if implied vol stays moderate; the setup is a catalyst-trade into Q1 guidance update, not a secular compounder until acquisition economics are disclosed.
• If already long, trim into strength ahead of the Q1 update and re-add on confirmation of MicroAge EBITDA/margin quality; the first print after closing is the cleanest falsifier/validation point.
• Watch HPE as a secondary beneficiary of the networking refresh, but prefer SCSC as the cleaner expression because supplier sell-through is better captured there than at the OEM level; only add HPE if Juniper supply normalizes in H2.
• No short recommendation on the stock at current levels; the balance-sheet and buyback support make the downside more of an integration/margin story than a demand story, so any short would need proof of channel conflict or sub-6% organic growth.